Now showing items 2372-2391 of 4635

    • Landscape of transcriptomic interactions between breast cancer and its microenvironment. 

      Fox, NS; Haider, S; Harris, AL; Boutros, PC (2019-07-15)
      Solid tumours comprise mixtures of tumour cells (TCs) and tumour-adjacent cells (TACs), and the intricate interconnections between these diverse populations shape the tumour's microenvironment. Despite this complexity, ...
    • Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. 

      Georgopoulou, D; Callari, M; Rueda, OM; Shea, A; Martin, A; Giovannetti, A; Qosaj, F; Dariush, A; Chin, S-F; Carnevalli, LS; Provenzano, E; Greenwood, W; Lerda, G; Esmaeilishirazifard, E; O'Reilly, M; Serra, V; Bressan, D; IMAXT Consortium; Mills, GB; Ali, HR; Cosulich, SS; Hannon, GJ; Bruna, A; Caldas, C (2021-03-31)
      The heterogeneity of breast cancer plays a major role in drug response and resistance and has been extensively characterized at the genomic level. Here, a single-cell breast cancer mass cytometry (BCMC) panel is optimized ...
    • Large expert-curated database for benchmarking document similarity detection in biomedical literature search. 

      Brown, P; RELISH Consortium; Zhou, Y (2019-01)
      Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that ...
    • Large Interobserver Variation in the International MR-LINAC Oropharyngeal Carcinoma Delineation Study 

      Blinde, S; Mohamed, ASR; Al-Mamgani, A; Newbold, K; Karam, I; Robbins, JR; Thomson, D; Fuller, CD; Raaijmakers, CP; Terhaard, C (ELSEVIER SCIENCE INC, 2017-10-01)
    • Large Stokes shift fluorescence activation in an RNA aptamer by intermolecular proton transfer to guanine. 

      Mieczkowski, M; Steinmetzger, C; Bessi, I; Lenz, A-K; Schmiedel, A; Holzapfel, M; Lambert, C; Pena, V; Höbartner, C (2021-06-10)
      Fluorogenic RNA aptamers are synthetic functional RNAs that specifically bind and activate conditional fluorophores. The Chili RNA aptamer mimics large Stokes shift fluorescent proteins and exhibits high affinity for ...
    • Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. 

      Loveday, C; Law, P; Litchfield, K; Levy, M; Holroyd, A; Broderick, P; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; UK Testicular Cancer Collaboration, The PRACTICAL Consortium; Reid, A; Huddart, RA; Houlston, RS; Turnbull, C (2018-09)
      Testicular germ cell tumour (TGCT) is the most common cancer in young men. Multiplex TGCT families have been well reported and analyses of population cancer registries have demonstrated a four- to eightfold risk to male ...
    • Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 

      Michailidou, K; Hall, P; Gonzalez-Neira, A; Ghoussaini, M; Dennis, J; Milne, RL; Schmidt, MK; Chang-Claude, J; Bojesen, SE; Bolla, MK; Wang, Q; Dicks, E; Lee, A; Turnbull, C; Rahman, N; Breast and Ovarian Cancer Susceptibility Collaboration; Fletcher, O; Peto, J; Gibson, L; Dos Santos Silva, I; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Czene, K; Irwanto, A; Liu, J; Waisfisz, Q; Meijers-Heijboer, H; Adank, M; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); van der Luijt, RB; Hein, R; Dahmen, N; Beckman, L; Meindl, A; Schmutzler, RK; Müller-Myhsok, B; Lichtner, P; Hopper, JL; Southey, MC; Makalic, E; Schmidt, DF; Uitterlinden, AG; Hofman, A; Hunter, DJ; Chanock, SJ; Vincent, D; Bacot, F; Tessier, DC; Canisius, S; Wessels, LFA; Haiman, CA; Shah, M; Luben, R; Brown, J; Luccarini, C; Schoof, N; Humphreys, K; Li, J; Nordestgaard, BG; Nielsen, SF; Flyger, H; Couch, FJ; Wang, X; Vachon, C; Stevens, KN; Lambrechts, D; Moisse, M; Paridaens, R; Christiaens, M-R; Rudolph, A; Nickels, S; Flesch-Janys, D; Johnson, N; Aitken, Z; Aaltonen, K; Heikkinen, T; Broeks, A; Veer, LJV; van der Schoot, CE; Guénel, P; Truong, T; Laurent-Puig, P; Menegaux, F; Marme, F; Schneeweiss, A; Sohn, C; Burwinkel, B; Zamora, MP; Perez, JIA; Pita, G; Alonso, MR; Cox, A; Brock, IW; Cross, SS; Reed, MWR; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Henderson, BE; Schumacher, F; Le Marchand, L; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; kConFab Investigators; Australian Ovarian Cancer Study Group; Lindblom, A; Margolin, S; Hooning, MJ; Hollestelle, A; van den Ouweland, AMW; Jager, A; Bui, QM; Stone, J; Dite, GS; Apicella, C; Tsimiklis, H; Giles, GG; Severi, G; Baglietto, L; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Müller, H; Arndt, V; Stegmaier, C; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Lissowska, J; Brinton, L; Goldberg, MS; Labrèche, F; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Hamann, U; Brüning, T; GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network; Radice, P; Peterlongo, P; Manoukian, S; Bonanni, B; Devilee, P; Tollenaar, RAEM; Seynaeve, C; van Asperen, CJ; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Bogdanova, NV; Antonenkova, NN; Dörk, T; Kristensen, VN; Anton-Culver, H; Slager, S; Toland, AE; Edge, S; Fostira, F; Kang, D; Yoo, K-Y; Noh, D-Y; Matsuo, K; Ito, H; Iwata, H; Sueta, A; Wu, AH; Tseng, C-C; Van Den Berg, D; Stram, DO; Shu, X-O; Lu, W; Gao, Y-T; Cai, H; Teo, SH; Yip, CH; Phuah, SY; Cornes, BK; Hartman, M; Miao, H; Lim, WY; Sng, J-H; Muir, K; Lophatananon, A; Stewart-Brown, S; Siriwanarangsan, P; Shen, C-Y; Hsiung, C-N; Wu, P-E; Ding, S-L; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Blot, WJ; Signorello, LB; Cai, Q; Zheng, W; Deming-Halverson, S; Shrubsole, M; Long, J; Simard, J; Garcia-Closas, M; Pharoah, PDP; Chenevix-Trench, G; Dunning, AM; Benitez, J; Easton, DF (2013-04)
      Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ∼9% of the familial risk of the disease. We ...
    • Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. 

      Campbell, J; Ryan, CJ; Brough, R; Bajrami, I; Pemberton, HN; Chong, IY; Costa-Cabral, S; Frankum, J; Gulati, A; Holme, H; Miller, R; Postel-Vinay, S; Rafiq, R; Wei, W; Williamson, CT; Quigley, DA; Tym, J; Al-Lazikani, B; Fenton, T; Natrajan, R; Strauss, SJ; Ashworth, A; Lord, CJ (2016-03-03)
      One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase ...
    • Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. 

      Litchfield, K; Loveday, C; Levy, M; Dudakia, D; Rapley, E; Nsengimana, J; Bishop, DT; Reid, A; Huddart, R; Broderick, P; Houlston, RS; Turnbull, C (2018-06)
      Testicular germ cell tumour (TGCT), the most common cancer in young men, has a significant heritable basis that has long raised questions as to the existence of underlying major high-penetrance susceptibility gene(s). To ...
    • Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. 

      Mancuso, N; Gayther, S; Gusev, A; Zheng, W; Penney, KL; Kote-Jarai, Z; Eeles, R; Freedman, M; Haiman, C; Pasaniuc, B; PRACTICAL consortium (2018-10-04)
      Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than 100 risk regions, most of the risk genes at these regions remain largely unknown. Here we integrate the largest PrCa GWAS ...
    • Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. 

      Jones, TM; De, M; Foran, B; Harrington, K; Mortimore, S (2016-05)
      This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Significantly new data have been published on laryngeal cancer management since the ...
    • Laser-free pelvic alignment in an online adaptive radiotherapy environment. 

      Barnes, H; Mohajer, J; Dunlop, A; Adair Smith, G; Herbert, T; Lawes, R; Tree, A; McNair, H (2020-03)
      The MR-Linac (MRL) provides a novel treatment modality that enables online adaptive treatments, but also creates new challenges for patient positioning in a laser-free environment. The accuracy and duration of prostate ...
    • Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. 

      Haviland, JS; Mannino, M; Griffin, C; Porta, N; Sydenham, M; Bliss, JM; Yarnold, JR; START Trialists' Group (2018-01)
      Background and purpose Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with ...

      Radford, J; Howell, S; Vaughan, K; Goode, V; Worthington, D; Yates-Bolton, N; Payne, E; Jenkins, J; Sibbering, M; Swerdlow, A; Cowan, R (FERRATA STORTI FOUNDATION, 2016-10-01)
    • Lead-time in the European Randomised Study of Screening for Prostate Cancer 

      Finne, P; Fallah, M; Hakama, M; Ciatto, S; Hugosson, J; de Koning, H; Moss, S; Nelen, V; Auvinen, A (ELSEVIER SCI LTD, 2010-11)
      Background: Lead-time is defined as the time by which screening advances the diagnosis compared with absence of screening. A sufficiently long lead-time needs to be achieved so that cancer can be detected while still ...
    • Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. 

      Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Waterhouse, A; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Allotey, D; Shafeek, S; Jenner, MW; Cook, G; Russell, NH; Kaiser, MF; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; UK NCRI Haematological Oncology Clinical Studies Group (2020-06-04)
      The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ...
    • Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. 

      Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Hockaday, A; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Jenner, MW; Cook, G; Russell, NH; Kaiser, MF; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; UK NCRI Haemato-oncology Clinical Studies Group (2019-01)
      BACKGROUND:Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ...
    • Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. 

      Pettitt, AR; Jackson, R; Cicconi, S; Polydoros, F; Yap, C; Dodd, J; Bickerstaff, M; Stackpoole, M; Khan, UT; Carruthers, S; Oates, M; Lin, K; Coupland, SE; Menon, G; Kalakonda, N; McCarthy, H; Bloor, A; Schuh, A; Duncombe, A; Dearden, C; Fegan, C; Kennedy, B; Walewska, R; Marshall, S; Fox, CP; Hillmen, P (2020-02-13)
    • Length of FMR1 repeat alleles within the normal range does not substantially affect the risk of early menopause. 

      Ruth, KS; Bennett, CE; Schoemaker, MJ; Weedon, MN; Swerdlow, AJ; Murray, A (2016-10)
      Study question Is the length of FMR1 repeat alleles within the normal range associated with the risk of early menopause?Summary answer The length of repeat alleles within the normal range does not substantially affect risk ...